2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 638

Are There Clinical Demographic or Subclinical Ultrasonographic Data That Can Predict Flare in Psoriatic Arthritis Patients during a Phase of Minimal Disease Activity after Spacing of Anti-TNF Blockers Injections?
Abstract Number: 2784

Are We over-Testing for Liver Enzyme Abnormalities in Rheumatoid Arthritis Patients Prescribed Methotrexate?
Abstract Number: 1133

Are We Ready? Changes in the Profile of Gout Patients over the Last 25 Years
Abstract Number: 2500

Are Work Outcomes Improved in Axial Spondyloarthritis (axSpA) Patients with Biologic Therapy? Results from the British Society for Rheumatology Register
Abstract Number: 920

Area-Level Predictors of Medication Nonadherence Among U.S. Medicaid Beneficiaries with Lupus: A Multilevel Study
Abstract Number: 2089

Arhalofenate Acid Inhibits Urate Crystal-Induced Inflammatory Responses through Activation of AMP-Activated Protein Kinase (AMPK) Signaling
Abstract Number: 10

Arterial Events in Primary Antiphospholipid Syndrome Are Associated with High Values of the Adjusted Global Antiphospholipid Syndrome Score
Abstract Number: 2355

Arterial Wave Reflection and Subclinical Atherosclerosis in Rheumatoid Arthritis
Abstract Number: 963

Artesunate Inhabits Migration and Invasion of Fibroblast-like Synoviocytes and Matrix Metalloproteinases Expression Via Suppression of PI3K/Akt Pathway in Rheumatoid Arthritis
Abstract Number: 1148

Arthritis after Cancer Immunotherapy: Symptom Duration and Treatment Response
Abstract Number: 1597

Arthritis and Hydroxychloroquine Are Associated with Decreased Risk of Macrophage Activation Syndrome Among Adults Hospitalized with SLE
Abstract Number: 1004

Arthritis Impact at the State and County Level — United States, 2015
Abstract Number: 251

Articular Cartilage of Knee and First MTP Joint Are the Preferred Sites of Urate Crystal Deposition in Asymptomatic Hyperuricemic Individuals
Abstract Number: 1337

ASN002, a Novel Dual SYK/JAK Inhibitor, Demonstrates Strong Efficacy in a Rat Model of Collagen-Induced Arthritis
Abstract Number: 1289

Assessing ACR/EULAR Provisional 2017 Classification Criteria for Granulomatosis with Polyangiitis (GPA) in a Cohort of 376 Children with Small to Medium Vessel Chronic Vasculitis – a Pediatric Vasculitis Initiative (PedVas) Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].